Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Pharmacopsychiatry ; 36(1): 7-11, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12649768

ABSTRACT

Repetitive transcranial magnetic stimulation (rTMS) has been shown to have a therapeutic effect on affective disorder and anxiety disorders. However, some reports have linked rTMS to a significant increase in anxiety in normal volunteers. This study investigates the effect of rTMS on anxiety and the use of acute and chronic paroxetine treatment on this animal model of anxiety. In normal rats, rTMS for 10 days induced anxiety, as shown by elevated plus maze, black and white box, and conditioned fear tests. This anxiety was suppressed by chronic, but not acute, paroxetine. These results suggest that rats receiving chronic rTMS treatment can be used as a model of anxiety and that the anxiety induced by rTMS might involve the serotonergic system.


Subject(s)
Anxiety/drug therapy , Paroxetine/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Transcranial Magnetic Stimulation , Acute Disease , Animals , Anxiety/etiology , Chronic Disease , Electric Stimulation , Fear/drug effects , Male , Maze Learning , Motor Activity/drug effects , Rats , Rats, Wistar
2.
Psychiatry Res ; 105(1-2): 123-7, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11740982

ABSTRACT

Disturbances of the dopaminergic neurotransmitter system have been associated with a personality trait that involves novelty seeking. A functional polymorphism in the promoter region of the dopamine D2 receptor gene (DRD2) has been reported to be associated with schizophrenia. We examined the association between this polymorphism in the DRD2 promoter region and personality traits, as assessed with the Tridimensional Personality Questionnaire. No significant association emerged between the polymorphism in the DRD2 promoter region and personality traits. Entering sex and age as covariates in an analysis of covariance did not change the results. These data fail to confirm an association between a polymorphism in the promoter region of the DRD2 and personality traits.


Subject(s)
Personality/genetics , Polymorphism, Genetic/genetics , Promoter Regions, Genetic , Receptors, Dopamine D2/genetics , Adult , Alleles , Arousal/genetics , Female , Genotype , Humans , Male , Personality Inventory , Reference Values
3.
Pharmacopsychiatry ; 34(6): 232-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11778143

ABSTRACT

We investigated the role of CCK in the development of anxiety by determining whether CCKB receptor antisense suppressed intracellular Ca(2+) concentration in vitro or suppressed conditioned fear stress in vivo. First, for the in vitro studies, we used rat pituitary tumor GH3 cells since these cells have CCKB receptors. GH3 cells were stimulated by 10 microM CCK-4; intracellular Ca(2+) concentration was measured. The CCKB receptor antisense at 1 or 10 microM reduced the subsequent response to 10 microM CCK-4 in a time-dependent manner. Second, for the in vivo studies, the CCKB receptor antisense, sense, random sense, or saline was infused at a constant rate for 6 days into rat lateral ventricles via mini-osmotic pumps. Individual rats were then subjected to 30 min of inescapable electric footshock in a chamber with a grid floor. Twenty-four hours later, the rat was again placed in the chamber and observed for 5 min without shocks. This study showed that CCKB receptor antisense significantly suppressed intracellular Ca(2+) concentration in GH3 cells and significantly reduced freezing behavior in rats, indicating that the CCKB receptor plays an important role in anxiety.


Subject(s)
Fear/physiology , Oligodeoxyribonucleotides, Antisense/pharmacology , Receptors, Cholecystokinin/genetics , Animals , Anxiety/physiopathology , Behavior, Animal/physiology , Calcium/metabolism , Conditioning, Psychological/physiology , Electroshock , Hippocampus/physiology , Lateral Ventricles , Male , Pituitary Neoplasms , Rats , Rats, Wistar , Receptor, Cholecystokinin B , Stress, Physiological/physiopathology , Tumor Cells, Cultured
4.
Pharmacopsychiatry ; 33(5): 189-93, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11071021

ABSTRACT

In order to examine the involvement of corticotropin-releasing hormone (CRF) receptor in the formation of anxiety, we investigated whether CRF receptor antagonist CP-154,526 suppressed conditioned fear stress. First, rats were individually subjected to 30 min of footshock. Twenty-four hours after footshock, the rats were again placed in the chamber and observed for 5 min without shock. CP-154,526 was administered 30 min before placing the rats in the chamber again. After that, CP-154,526 was once more administered 30 min before applying footshock. Administration of CP-154,526 30 min both before conditioned fear stress (placing the rats inside the cage but not applying footshock) and before actual footshock significantly reduced freezing behavior. These results show that CP-154,526 blocked both the acquisition and expression of conditioned fear, thus suggesting that the CRF receptor might be related to anxiety.


Subject(s)
Fear/drug effects , Pyrimidines/pharmacology , Pyrroles/pharmacology , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Animals , Conditioning, Psychological , Electroshock , Male , Motor Activity/drug effects , Rats , Rats, Wistar
5.
Neuropeptides ; 34(3-4): 234-9, 2000.
Article in English | MEDLINE | ID: mdl-11021986

ABSTRACT

Corticotropin releasing factor (CRF) is a major mediator of adaptive responsiveness to stress. We measured changes in extracellular concentrations of catecholamine and indoleamines in freely moving rats in response to administration of CRF1 antagonist CP-154,526 by using in vivo microdialysis. Dialysis probes were placed stereotaxically in either the hippocampus or the prefrontal cortex. We examined the response in the hippocampus or the prefrontal cortex to 32.0 mg/kg i.p. administration of CP-154,526. CP-154,526 reduced the extracellular concentration of norepinephrine (NE) from 30 min to 180 min and 5-hydroxytryptamine (5-HT) from 30 min to 60 min after injection in the hippocampus. CP-154,526 did not remarkably change dopamine (DA). There were no significant differences between CP-154,526 and vehicle in NE, 5-HT and DA in the prefrontal cortex. The present results indicate that CRF1 receptor antagonist produced a decrease in dialysate concentration of NE and 5-HT, but not DA, in the hippocampus. These results suggest that the CRH-1 receptor antagonist suppresses the release of NE and 5-HT in the hippocampus.


Subject(s)
Dopamine/metabolism , Hippocampus/metabolism , Norepinephrine/metabolism , Prefrontal Cortex/metabolism , Pyrimidines/pharmacology , Pyrroles/pharmacology , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Serotonin/metabolism , Animals , Chromatography, High Pressure Liquid , Extracellular Space/metabolism , Hippocampus/drug effects , Kinetics , Male , Microdialysis , Prefrontal Cortex/drug effects , Rats , Rats, Wistar
6.
Brain Res Bull ; 53(6): 789-92, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11179844

ABSTRACT

Cholecystokinin (CCK) may have a role in the mediation of human panic disorder and anxiogenic (anxiolytic)-like activity in an animal model of anxiety. Otsuka Long Evans Tokushima Fatty (OLETF) rats lacked CCK A receptors (CCKAR) because of a genetic abnormality. In order to elucidate the involvement of CCKAR in the regulation of anxiety, we investigated the exploratory behavior on elevated plus-maze test, the black and white box test, and open field test with OLETF rats in comparison with normal [Long-Evans Tokushima Otsuka (LETO)] rats. And OLETF rats increased the number of stretched attend postures and decreased open arm entry and the % time of open arm in an elevated plus-maze test. Time spent in the white box decreased significantly in OLETF rats than LETO rats. The total line crossing decreased significantly in OLETF rats compared to LETO rats. The missing CCKAR had a significant anxiogenic-like effect. These data support the involvement of the CCKAR in the neurobiological mechanism of anxiety.


Subject(s)
Anxiety/metabolism , Brain/metabolism , Cholecystokinin/metabolism , Rats, Inbred OLETF/metabolism , Receptors, Cholecystokinin/deficiency , Animals , Anxiety/physiopathology , Brain/physiopathology , Exploratory Behavior/physiology , Male , Maze Learning/physiology , Rats , Receptor, Cholecystokinin A , Receptors, Cholecystokinin/genetics
7.
Biol Psychiatry ; 45(3): 368-70, 1999 Feb 01.
Article in English | MEDLINE | ID: mdl-10023516

ABSTRACT

BACKGROUND: Polymorphism in the serotonin transporter promoter gene has been recently reported to be associated with the personality trait known as anxiety-related traits. We have attempted to replicate these findings in 101 healthy Japanese subjects. METHODS: The personality traits of the subjects were assessed with the tridimensional personality questionnaire. RESULTS: An association was observed in the present study between individuals grouped according to the transporter gene and harm avoidance scores. CONCLUSIONS: These data supported that there was an association between the serotonin transporter gene and anxiety.


Subject(s)
Anxiety/genetics , Carrier Proteins/genetics , Genetic Predisposition to Disease/genetics , Membrane Glycoproteins/genetics , Membrane Transport Proteins , Nerve Tissue Proteins , Personality/genetics , Polymorphism, Genetic/genetics , Adult , Alleles , Analysis of Variance , Chi-Square Distribution , Female , Genotype , Humans , Japan/ethnology , Male , Neurotic Disorders/genetics , Polymerase Chain Reaction , Serotonin Plasma Membrane Transport Proteins
8.
Neuropeptides ; 33(6): 483-6, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10657528

ABSTRACT

In order to examine the involvement of CCK in the formation of anxiety, we have investigated whether CCKB receptor antagonist PD135158 suppressed conditioned fear stress. Rats were individually subjected to 30 min of inescapable electric footshock in a chamber with a grid floor. First, the rats were individually subjected to 30 min of footshock. Twenty-four h after the footshock, the rats were again placed in the chamber and observed for 5 min without shocks. PD135158 was administered 30 min before placing the rats in the chamber again. Secondly, PD135158 was administered 30 min before footshock. Thirdly, PD135158 was administered 5 min after footshock. Administration of PD135158 30 min before conditioned fear stress significantly reduced freezing behavior. Administration of PD135158 30 min before footshock also significantly reduced freezing behavior. But, administration of PD135158 5 min after footshock did not significantly reduce freezing behavior. PD135158 blocked not only the acquisition but also the expression of conditioned fear. These results suggest that the CCKB receptor might play an important role in conditioned fear stress and that it might be related to anxiety.


Subject(s)
Anti-Anxiety Agents/pharmacology , Conditioning, Psychological/drug effects , Fear/drug effects , Indoles/pharmacology , Meglumine/analogs & derivatives , Receptors, Cholecystokinin/antagonists & inhibitors , Animals , Anxiety/drug therapy , Brain Chemistry/drug effects , Electroshock , Male , Meglumine/pharmacology , Memory/drug effects , Motor Activity/drug effects , Panic Disorder/drug therapy , Rats , Rats, Wistar , Receptor, Cholecystokinin B
9.
Article in Japanese | MEDLINE | ID: mdl-9592807

ABSTRACT

The aim of this study is to determine whether or not CCKB receptor antagonist PD135158 suppresses conditioned fear. Rats were individually subjected to 30 min of inescapable electric footshock in a chamber with a grid floor. PD135158 or the vehicle was administered 30 min before placing the rats in the shock chamber again. The rats were observed for 5 min without receiving shock. The administration of PD135158 30 min before conditioned-fear stress significantly reduced freezing behavior. PD135158 blocked the expression of conditioned fear. PD135158 was again administered 30 min before footshock. Then, the rats were individually subjected to 30 min of inescapable electric footshock in the shock chamber. Twenty-four hours after receiving footshock, the rats were again placed in the shock chamber and observed for 5 min without shock administration. The administration of PD135158 30 min before footshock significantly reduced conditioned freezing. PD135158 blocked the anxiety of conditioned fear. PD135158 blocked not only the anxiety, but also the expression of conditioned fear. These results suggest that CCKB receptor might play an important role in conditioned-fear stress. They indicate that CCKB receptor is related to anxiety.


Subject(s)
Anti-Anxiety Agents/therapeutic use , Indoles/therapeutic use , Meglumine/analogs & derivatives , Panic Disorder/drug therapy , Receptors, Cholecystokinin/antagonists & inhibitors , Animals , Anti-Anxiety Agents/pharmacology , Conditioning, Psychological , Disease Models, Animal , Indoles/pharmacology , Male , Meglumine/pharmacology , Meglumine/therapeutic use , Rats , Rats, Wistar , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/physiology
10.
Psychiatry Res ; 81(3): 381-6, 1998 Dec 14.
Article in English | MEDLINE | ID: mdl-9925189

ABSTRACT

This study examined the relationship between the Symptom Checklist 90 (SCL-90), Maudsley Personality Inventory (MPI) and cholecystokinin 4 (CCK4)-induced intracellular calcium response in T cells. Fifty-two normal volunteers were 37 males and 15 females; they ranged in age from 23 to 44 years. Measures included CCK4-induced intracellular calcium response in T cells, SCL-90 scores, and MPI. Paranoid ideation and interpersonal sensitivity in SCL-90 showed a significant negative association with CCK4-induced intracellular calcium response. Absent were sex differences and extroversion and neuroticism correlations. There were no significant differences between men and women in SCL-90 or MPI scores. There was no correlation among extroversion and neuroticism and CCK4-induced intracellular calcium response. CCKB receptor function might play a role in paranoid ideation and interpersonal sensitivity.


Subject(s)
Calcium Channels/drug effects , Personality Disorders/diagnosis , Personality Inventory/statistics & numerical data , T-Lymphocytes/drug effects , Tetragastrin , Adult , Anxiety Disorders/diagnosis , Anxiety Disorders/physiopathology , Calcium/metabolism , Calcium Channels/physiology , Extraversion, Psychological , Female , Humans , Introversion, Psychological , Male , Personality Disorders/physiopathology , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/drug effects , Receptors, Cholecystokinin/physiology
12.
Biol Psychiatry ; 39(12): 1000-8, 1996 Jun 15.
Article in English | MEDLINE | ID: mdl-8780834

ABSTRACT

Serotonin 5-HT2C receptor-mediated intracellular Ca2+ mobilization was investigated in 5-HT2C receptors expressed in Chinese hamster ovary (CHO) cells; and fura-2/AM was used to investigate the regulation of 5-HT2C receptor function. CHO cells, transfected with a cDNA clone for the 5-HT2C receptor, expressed 287 fmol/mg of the receptor protein as determined by mianserin-sensitive [3H]-mesulergine binding (kd = 0.49 nM). The addition of 5-HT mobilized intracellular Ca2+ in a dose-dependent fashion, ranging from basal level of 99 +/- 1.8 nM up to 246 +/- 21.2 nM, with an EC50 value for 5-HT of .015 microM. Exposure to 5-HT, a 5-HT receptor agonist, mCPP [1-(3-chlorophenyl)piperazine dihydrochloride], a 5-HT2C agonist, and DOI [1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane], a 5-HT2C and 5-HT2 agonist, resulted in increased intracellular Ca2+ levels. Mianserin, mesulergine, ritanserin, and ketanserin each blocked 5-HT-mediated intracellular Ca2+ mobilization more effectively than spiperone. Mianserin and amoxapine inhibited 5-HT-mediated intracellular Ca2+ mobilization completely; amitriptyline, nortriptyline, and imipramine reduced it about 50%. These results suggest that antagonism in CHO cells transfected with human 5-HT2C receptors is a component of the serotonergic properties of a number of established antidepressants.


Subject(s)
Antidepressive Agents/pharmacology , Calcium Channels/genetics , Calcium/metabolism , Intracellular Fluid/drug effects , Receptors, Serotonin/genetics , Transfection/genetics , Animals , Antidepressive Agents, Second-Generation/pharmacology , CHO Cells , Calcium Channels/drug effects , Cricetinae , Ergolines/pharmacokinetics , Humans , Mianserin/pharmacology , Radioligand Assay , Receptors, Serotonin/classification , Receptors, Serotonin/drug effects , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology , Signal Transduction/drug effects , Signal Transduction/genetics
13.
J Neurochem ; 66(4): 1610-6, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8627317

ABSTRACT

We investigated the effects of brain cholecystokinin (CCK) receptors on the intracellular calcium concentration and protein kinase C in human T cells. CCK-4 produced a transient increase in calcium in the absence of extracellular calcium. CCK-B agonists stimulated calcium mobilization in a dose-dependent manner in T cells. CCK-B antagonists suppressed CCK-4-induced calcium mobilization more potently than CCK-A antagonist. The recovery of desensitization of the CCK-4-induced response was delayed by phosphoserine/phosphothreonine phosphatase inhibitor, calyculin A. The responsiveness to CCK-4 was also reduced by phorbol 12,13-dibutyrate (PDBu), and this effect of PDBu was abolished completely by preincubation with staurosporine. CCK-4-induced calcium mobilization was too small to attribute the desensitization to the protein kinase C transduction pathway. T cells from patients with untreated panic disorder exhibited significantly higher cholecystokinin-4-induced calcium mobilization than those from healthy controls or patients with treated panic disorder. These results suggest that cholecystokinin-B receptor function in T cells of patients with panic disorder is enhanced. Cholecystokinin-4-induced calcium mobilization in T cells may be state dependent and useful as a biological marker of panic disorder.


Subject(s)
Calcium/metabolism , Panic Disorder/metabolism , T-Lymphocytes/metabolism , Tetragastrin/pharmacology , Adult , Alprazolam/pharmacology , Biomarkers , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Nootropic Agents/pharmacology , Panic Disorder/immunology , Pentagastrin/pharmacology , Receptors, Cholecystokinin/drug effects , Receptors, Cholecystokinin/metabolism , Sincalide/analogs & derivatives , Sincalide/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/ultrastructure , Tetragastrin/agonists , Tetragastrin/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...